Medulloblastom (PNET) u dětí - současné možnosti diagnostiky a léčby
| Title in English | Medulloblastoma (PNET) in children - present management |
|---|---|
| Authors | |
| Year of publication | 2006 |
| Type | Article in Periodical |
| Magazine / Source | Klinická onkologie |
| MU Faculty or unit | |
| Citation | |
| Field | Paediatry |
| Keywords | medulloblastoma; chemotherapy; prognostic factors; molecular target therapy |
| Description | Review. Medulloblastoma represent the most common malignant brain tumor of childhood. This tumor is uniquely sensitive to chemotherapy and radiotherapy, but successful surgical removal remains to be an important part of therapy. A great progress in the treatment of medulloblastoma has been made in the last decades thanks to improved neurosurgical techniques, radiotherapy and optimized adjuvant chemotherapy. Medulloblastoma is currently stratified into high and standard (average) risk categories depending on clinical and radiological factors. The developing era of molecular biology is bringing new possibilities of prognostic factors identification and risk-adapted therapy. The treatment of average-risk medulloblastoma has achieved an important improvement, that allows efforts to be focused on the reduction of adverse treatment effects (especially radiotherapy). Children with high-risk disease (mainly infants) have still an unsatisfactory prognosis, despite the introducing of high-dose chemotherapy to the therapeutic options. Many clinical trials focus on new defined molecular targets and specific drugs with capacibility to hit these adequate signal pathways (so-called molecular targeted therapy). |
| Related projects: |